Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Sells 30,000 Shares

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) CEO Christopher Gibson sold 30,000 shares of the business’s stock in a transaction on Wednesday, August 7th. The stock was sold at an average price of $7.10, for a total value of $213,000.00. Following the sale, the chief executive officer now owns 758,738 shares of the company’s stock, valued at approximately $5,387,039.80. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink.

Christopher Gibson also recently made the following trade(s):

• On Wednesday, July 10th, Christopher Gibson sold 50,000 shares of Recursion Pharmaceuticals stock. The stock was sold at an average price of $7.48, for a total value of $374,000.00.
• On Wednesday, June 5th, Christopher Gibson sold 50,000 shares of Recursion Pharmaceuticals stock. The shares were sold at an average price of $8.42, for a total transaction of $421,000.00.

Recursion Pharmaceuticals Trading Down 5.3 %

Shares of RXRX stock traded down $0.35 on Friday, reaching $6.29. The company had a trading volume of 8,665,672 shares, compared to its average volume of 6,060,540. The stock has a market cap of $1.49 billion, a PE ratio of -4.09 and a beta of 0.83. The company has a 50-day moving average of $8.16 and a 200-day moving average of $9.36. Recursion Pharmaceuticals, Inc. has a 12 month low of $4.97 and a 12 month high of $15.74.

Recursion Pharmaceuticals (NASDAQ:RXRX) last posted its earnings results on Thursday, August 8th. The company reported ($0.40) earnings per share for the quarter, missing the consensus estimate of ($0.35) by ($0.05). Recursion Pharmaceuticals had a negative return on equity of 79.96% and a negative net margin of 765.90%. The firm had revenue of $14.42 million during the quarter, compared to analyst estimates of $11.96 million. During the same quarter last year, the business posted ($0.38) earnings per share. The company’s revenue for the quarter was up 30.9% on a year-over-year basis. Sell-side analysts anticipate that Recursion Pharmaceuticals, Inc. will post -1.56 earnings per share for the current year.

Analyst Ratings Changes

A number of equities analysts have issued reports on RXRX shares. KeyCorp reduced their price objective on shares of Recursion Pharmaceuticals from $16.00 to $12.00 and set an “overweight” rating on the stock in a research note on Thursday, July 11th. Needham & Company LLC cut their price target on Recursion Pharmaceuticals from $17.00 to $16.00 and set a “buy” rating on the stock in a research note on Friday.

Institutional Inflows and Outflows

Several hedge funds and other institutional investors have recently added to or reduced their stakes in the business. National Bank of Canada FI lifted its stake in Recursion Pharmaceuticals by 90.9% in the fourth quarter. National Bank of Canada FI now owns 3,150 shares of the company’s stock valued at $31,000 after buying an additional 1,500 shares in the last quarter. Wedmont Private Capital lifted its position in Recursion Pharmaceuticals by 11.8% in the 1st quarter. Wedmont Private Capital now owns 18,943 shares of the company’s stock valued at $172,000 after acquiring an additional 2,000 shares in the last quarter. Interchange Capital Partners LLC boosted its stake in Recursion Pharmaceuticals by 7.3% in the 2nd quarter. Interchange Capital Partners LLC now owns 34,580 shares of the company’s stock worth $268,000 after purchasing an additional 2,349 shares during the period. Benjamin F. Edwards & Company Inc. bought a new position in Recursion Pharmaceuticals during the 1st quarter worth about $26,000. Finally, Victory Capital Management Inc. raised its stake in shares of Recursion Pharmaceuticals by 13.5% in the 2nd quarter. Victory Capital Management Inc. now owns 21,891 shares of the company’s stock valued at $164,000 after purchasing an additional 2,598 shares during the period. 89.06% of the stock is currently owned by institutional investors.

Recursion Pharmaceuticals Company Profile

Recursion Pharmaceuticals, Inc operates as a clinical-stage biotechnology company, engages in the decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering to industrialize drug discovery. The company develops REC-994, which is in Phase 2 clinical trial to treat cerebral cavernous malformation; REC-2282, which is in Phase 2/3 clinical trial for the treatment of neurofibromatosis type 2; REC-4881, which is in Phase 1b/2 clinical trial to treat familial adenomatous polyposis; REC-3964, which is in Phase 1 clinical trial to treat Clostridioides difficile infection; and REC-4881, which is in Phase 2 clinical trial to treat AXIN1 or APC mutant cancers.